Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Clinical Oncology

• Publication date

  1996-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1996.14.2.610PMID 8636778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.

  1994cited by this paper
• Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?

  1994cited by this paper
• Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

  1992cited by this paper
• Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.

  1992cited by this paper
• Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

  1992cited by this paper
• Multidrug resistance in human cancer.

  1992cited by this paper
• Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

  1991cited by this paper
• Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.

  1991cited by this paper
• In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

  1991cited by this paper
• P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.

  1991cited by this paper
• Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected].

  1991cited by this paper
• Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.

  1990cited by this paper
• Expression of Multidrug Resistance Gene in Human Cancers

  1989cited by this paper
• Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

  1989cited by this paper
• Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit.

  1988cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Multiple-drug resistance in human cancer.

  1987cited by this paper
• Expression of a multidrug-resistance gene in human tumors and tissues.

  1987cited by this paper
• Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.

  1986cited by this paper
• Etoposide pharmacokinetics in patients with normal and abnormal organ function.

  1986cited by this paper
• Genetic and biochemical characterization of multidrug resistance.

  1985cited by this paper
• Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.

  1984cited by this paper

• Terpenoids: Emerging Natural Modulators for Reversing ABC Transporter-Mediated Multidrug Resistance in Cancer Chemotherapy

  2026cites this paper
• A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors

  2023cites this paper
• Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

  2022cites this paper
• Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition.

  2021cites this paper
• Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

  2020cites this paper
• Efflux transporters in cancer resistance: Molecular and functional characterization of P-glycoprotein

  2020cites this paper
• Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.

  2018cites this paper
• Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions

  2017cites this paper
• A newly synthesized nickel chelate can selectively target and overcome multidrug resistance in cancer through redox imbalance both in vivo and in vitro

  2017cites this paper
• Characterization of the membrane transporter OATP1A2 activity towards different classes of drugs

  2017cites this paper
• Asclepiasterol, a novel C21 steroidal glycoside derived from Asclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression

  2016cites this paper
• Targeting Chemotherapy Resistance in Glioblastoma Through Modulation of ABC Transporters

  2016cites this paper
• Quantitative Estimation of P-glycorptein-Mediated Drug Transport by Mechanistically Modeled Intrinsic Clearance

  2015cites this paper
• Prodrug strategies for brain delivery

  2015cites this paper
• Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

  2015cites this paper
• The role of P-glycoprotein in drug resistance in multiple myeloma

  2015cites this paper
• Drug Transporters in the Central Nervous System

  2015cites this paper
• 抗がん剤治療時における P-glycoproteinの発現・機能変動と薬物動態並びに薬理作用へ及ぼす影響

  2014cites this paper
• Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.

  2014cites this paper
• Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs.

  2014cites this paper
• Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

  2014cites this paper
• P-glycoprotein (P-gp/MDR1)/ABCB1

  2013cites this paper
• Enhancing macrocyclic diterpenes as multidrug-resistance reversers: structure-activity studies on jolkinol D derivatives.

  2013cites this paper
• meeting held in San Diego, CA, December 1997. 833 (Valspodar) : Presented in part at the American Society of Hematology Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With

  2013cites this paper
• The molecular interaction of a copper chelate with human P-glycoprotein

  2012cites this paper
• Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs

  2012cites this paper
• Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) for the solubilization and in vivo delivery of valspodar.

  2012cites this paper
• Comportamiento del Programa Nacional de Control de cáncer cervicouterino en un área de salud de La Habana, Cuba

  2012cites this paper
• ABC Drug Transporters and Their Impact on Drug Disposition/Drug Sensitivity and Resistance

  2012cites this paper
• Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

  2012cites this paper
• Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

  2012cites this paper
• Sesquiterpenos dihidro-β-agarofuranos como revertidores naturales de la resistencia celular a múltiples fármacos causada por la Glicoproteína-P MDR1 humana

  2011cites this paper
• Investigation of the intrinsic mechanism of drug resistance in multiple myeloma

  2011cites this paper
• Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat.

  2010cites this paper
• Introduction to Drug Transporters

  2010cites this paper
• Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat

  2010cites this paper
• Immunosuppressors as multidrug resistance reversal agents.

  2010cites this paper
• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  2009cites this paper
• The ABC Transporters: Structural Insights into Drug Transport

  2009cites this paper
• Chapter 3 Multidrug resistance protein 2 ( Mrp 2 ; Abcc 2 ) is an important determinant of paclitaxel pharmacokinetics

  2009cites this paper
• Reversal Agents for P‐Glycoprotein‐Mediated Multidrug Resistance

  2009cites this paper
• Generating Inhibitors of P-Glycoprotein: Where to, Now?

  2009cites this paper
• Pharmacological functions of multidrug transporters: studies employing combination transporter knockout mice

  2009cites this paper
• Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma.

  2008cites this paper
• Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

  2008cites this paper
• ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance.

  2007cites this paper
• Transporter-mediated drug interactions: clinical implications and in vitro assessment

  2007cites this paper
• Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

  2007cites this paper
• How can we best use structural information on P-glycoprotein to design inhibitors?

  2007cites this paper
• Enaminones: Exploring additional therapeutic activities.

  2007cites this paper
• Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.

  2007cites this paper
• MULTIDRUG RESISTANCE MARKERS OF HUMAN SOLID TUMORS: METHODICAL, FUNDAMENTAL AND CLINICAL ASPECTS

  2006cites this paper
• An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy.

  2006cites this paper
• Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.

  2006cites this paper
• Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics

  2006cites this paper
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.

  2005cites this paper
• Het prognostisch belang van P-glycoproteïne bij kinderen met acute lymfoblasten leukemie en neuroblastomen

  2005cites this paper
• The effect of excipients on pharmacokinetic parameters of parenteral drugs

  2005cites this paper
• Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

  2005influential citation
• The effect of excipients on pharmacokinetic parameters of parenteral drugs

  2005cites this paper
• A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.

  2005cites this paper
• Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies

  2005cites this paper
• Immunosuppressors and reversion of multidrug-resistance.

  2005cites this paper
• Efflux transporters and their clinical relevance.

  2005cites this paper
• Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain

  2005cites this paper
• Phase ICombining a P-Glycoprotein Inhibitor , MS 209 , in Combinationwith Docetaxel in Patients with AdvancedMalignancies

  2005cites this paper
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

  2004cites this paper
• A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma

  2004cites this paper
• Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

  2004cites this paper
• THE TRANSPORT AND MODULATION OF HIV PROTEASE INHIBITORS INTO THE RAT CENTRAL NERVOUS SYSTEM AND MILK

  2004cites this paper
• A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

  2004cites this paper
• PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.

  2004cites this paper
• Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

  2004cites this paper
• Overcoming Drug Resis tance in Mult ip le Myeloma : The Emergence of Therapeut ic Approaches to Induce Apoptos is

  2003cites this paper
• Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.

  2003cites this paper
• Evaluation of P‐glycoprotein—Mediated Renal Drug Interactions in an MDR1‐MDCK Model

  2003cites this paper
• Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

  2003cites this paper
• Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?

  2003cites this paper
• A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.

  2003cites this paper
• Multidrug resistance reversal agents.

  2003cites this paper
• Effect of valspodar on the pharmacokinetics of unbound paclitaxel

  2003cites this paper
• Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

  2003cites this paper
• Clinical Relevance of P-Glycoprotein in Drug Therapy

  2003cites this paper
• Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

  2003cites this paper
• Klinicky relevantní lékové interakce v onkologii

  2003cites this paper
• Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET

  2003cites this paper
• Pharmacological Effects of Formulation Vehicles

  2003cites this paper
• A guide to clinically relevant drug interactions in oncology

  2003cites this paper
• SOLVING THE PROBLEM OF MULTIDRUG RESISTANCE: ABC TRANSPORTERS IN CLINICAL ONCOLOGY

  2003cites this paper
• Pharmacokinetics in Cancer Treatment

  2002cites this paper
• Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.

  2002cites this paper
• Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

  2002cites this paper
• A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies

  2002cites this paper
• Pharmacokinetic Study of Infusional Valspodar

  2002cites this paper
• The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice

  2002cites this paper
• Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration

  2002cites this paper
• Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

  2002cites this paper
• Contribution of efflux pump activity to the delivery of pulmonary therapeutics.

  2002cites this paper
• Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study.

  2002cites this paper
• Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance

  2001cites this paper